Skip to main content

Yeaman Kevin J's Form 4 filing

Dolby Laboratories, Inc. (DLB) · filed May 18, 2023

Accession no.
0001209191-23-030821
Filed
May 18, 2023
Trade date
May 16, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $755.4K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Yeaman Kevin JCIK 0001200469Director, Officer (President and CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 16, 2023Class A Common StockMOption exerciseAcquired+9,030$42.98+$388,109.460,909Indirect
May 16, 2023Class A Common StockSSaleDisposed−9,030$83.65F1−$755,359.551,879Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
May 16, 2023Class A Common StockMOption exerciseDisposed−9,030$0.00$0162,786Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The shares were sold in multiple transactions at prices ranging from $83.24 to $84. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

Referenced by the price of 1 transaction in Table I.

Remarks

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 28, 2022 which was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) in effect at the time of adoption.

Read the full filing on SEC EDGAR (opens in a new tab)